![]() | |
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.162.062 ![]() |
Chemical and physical data | |
Formula | C22H21Cl2IN4O |
Molar mass | 555.24 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
AM-251 is an inverse agonist at the CB1 cannabinoid receptor. AM-251 is structurally very close to rimonabant; both are biarylpyrazole cannabinoid receptor antagonists. In AM-251, the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group. The resulting compound exhibits slightly better binding affinity for the CB1 receptor (with a Ki value of 7.5 nM) than rimonabant, which has a Ki value of 11.5 nM, AM-251 is, however, about two-fold more selective for the CB1 receptor when compared to rimonabant.[1] Like rimonabant, it is additionally a μ-opioid receptor antagonist[2] that attenuates analgesic effects.[3]
AM251 has shown an in vitro antimelanoma activity against pancreatic and colon cancer cells.[4]
See also
References
- ^ Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. (February 1999). "Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists". Journal of Medicinal Chemistry. 42 (4): 769–76. doi:10.1021/jm980363y. PMID 10052983.
- ^ Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL (October 2012). "AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies". Neuropharmacology. 63 (5): 905–15. doi:10.1016/j.neuropharm.2012.06.046. PMC 3408547. PMID 22771770.
- ^ Seely, Kathryn A.; Brents, Lisa K.; Franks, Lirit N.; Rajasekaran, Maheswari; Zimmerman, Sarah M.; Fantegrossi, William E.; Prather, Paul L. (October 2012). "AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies". Neuropharmacology. 63 (5): 905–915. doi:10.1016/j.neuropharm.2012.06.046. PMC 3408547. PMID 22771770.
- ^ Carpi, Sara; Fogli, Stefano; Romanini, Antonella; Pellegrino, Mario; Adinolfi, Barbara; Podestà, Adriano; Costa, Barbara; Da Pozzo, Eleonora; Martini, Claudia; Breschi, Maria Cristina; Nieri, Paola (August 26, 2015). "AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells" (PDF). Anticancer Drugs. 26 (7): 754–62. doi:10.1097/CAD.0000000000000246. PMID 25974027. S2CID 205526223. Archived (PDF) from the original on July 2, 2021. Retrieved July 3, 2021.
Receptor (ligands) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||
Enzyme (modulators) |
| ||||||||||||
Others |
| ||||||||||||
|
MOR |
|
---|---|
DOR |
|
KOR |
|
NOP |
|
Unsorted | |
Others |
|